ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by American Century Companies Inc.

American Century Companies Inc. reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,248 shares of the specialty pharmaceutical company's stock after selling 27,239 shares during the period. American Century Companies Inc. owned approximately 0.29% of ANI Pharmaceuticals worth $3,331,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ANIP. US Bancorp DE boosted its position in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the period. KBC Group NV lifted its position in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after acquiring an additional 579 shares during the period. HighTower Advisors LLC purchased a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $222,000. Finally, Hohimer Wealth Management LLC acquired a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $264,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

ANIP has been the subject of several analyst reports. Guggenheim restated a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Friday. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group began coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They set a "buy" rating and a $80.00 target price on the stock. StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

Insider Activity

In other news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,200 shares of company stock worth $191,776. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Stock Up 4.6 %

ANI Pharmaceuticals stock traded up $3.00 during midday trading on Friday, hitting $68.12. The stock had a trading volume of 291,286 shares, compared to its average volume of 267,570. The business has a fifty day moving average price of $62.34 and a 200 day moving average price of $59.07. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.00. The stock has a market cap of $1.48 billion, a P/E ratio of -123.85 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.